logo
Can a 30-Minute Brain Boost Fix the Way We Feel? Inside the Rise of Exomind

Can a 30-Minute Brain Boost Fix the Way We Feel? Inside the Rise of Exomind

America is emotionally running on fumes. The latest data from the World Happiness Report, according to a recent press release, puts the U.S. at an all-time low in global rankings. At the same time, findings from the Ipsos Global Health Service Monitor reveal that mental wellness has now eclipsed cancer as the top health concern in North America. Not heart disease. Not diabetes. But stress, burnout, and emotional fatigue are what have people most worried.
We're collectively tapped out, and it shows.
But if the past few years have taught us anything, it's that mental health isn't a side quest; it's central to everything else. And now, a new frontier in non-invasive brain science might be stepping in where therapy and meds leave off. It's called Exomind. And while it sounds like the name of an AI villain in a Marvel movie, it might just become your brain's new best friend.
Transcranial Magnetic Stimulation, or TMS, was invented in 1985 and cleared by the FDA in 2008 for treatment-resistant depression. Often used when standard treatments fall short, TMS has shown notable effectiveness with minimal side effects.
Enter Exomind, a next-generation version of this proven technology that brings the power of neuroscience out of the ivory tower and into your neighborhood doctor's office. Using its proprietary ExoTMS™ platform, Exomind promises to rewire how we approach brain health by democratizing access to TMS, making it sleeker, faster, more comfortable, and astonishingly accessible.
The idea of a non-invasive, drug-free brain boost sounds futuristic. But Dr. Georgine Nanos, MD, MPH, a family medicine physician and early adopter of Exomind, says that most responsive patient groups include:
'We had a patient who hadn't been able to connect with her newborn. After just a few sessions, she told me it was like the light switched on again,' says Dr. Nanos. 'That's not placebo. That's neuroscience doing its job.'
'We're enhancing neuroplasticity,' Dr. Nanonos explains. 'We're helping the brain learn, adapt, and recover faster.' Think of it as clearing out the mental traffic jam so you can reach emotional clarity more efficiently.'
ExoTMS™ uses a focused magnetic field to stimulate specific areas of the brain involved in emotional regulation, cognitive function, and self-control. By targeting the prefrontal cortex and other mood-related zones, the device helps build new neural pathways, effectively retraining the brain to process emotions and thoughts more constructively.
Each session delivers repetitive magnetic pulses to underactive brain regions, aiming to restore balance in the neural circuits that govern mood and cognition. Sessions are typically well-tolerated, with a low risk of side effects, and can be done without anesthesia or sedation, allowing patients to resume normal activities immediately.
Clinical studies show promising outcomes: 50% of patients experience a reduction in depressive symptoms within four weeks, while 58% achieve sustained remission at 12 months. For treatment-resistant cases, 65% show significant improvement. In layman's terms: it helps your brain stop spiraling, catastrophizing, or shutting down.
Instead, it strengthens the circuitry responsible for calm, clarity, and decision-making.
Unlike older TMS systems that could feel pinchy or intense, Exomind's version is said to be sensationless. Patients recline in a chair and let the machine do its work for 30 minutes. Most complete a series of six sessions over one to three weeks. There's no anesthesia, no recovery time, and no drama. Just a quiet reboot.
The timing couldn't be better. We're living in an age where self-optimization has gone mainstream. Biohacking and cryotherapy are no longer fringe tools but trending hashtags. Yet what sets Exomind apart is its clinical backbone. This isn't a gadget or wellness gimmick; it's FDA-cleared medical technology. And by embedding itself into primary care and OB/GYN offices (where 80% of mental wellness care happens), Exomind is positioning itself not as an alternative, but as an evolution.
'Think of it like a Peloton for your prefrontal cortex,' jokes one Los Angeles patient who completed a treatment series in February, according to an Exomind press statement. 'I didn't want meds. I just wanted to stop feeling like I was constantly on edge. After the second session, I started sleeping through the night.'
It may have taken a global mental health reckoning to get us here, but the message is clear: your brain deserves as much maintenance as your body. With technologies making once-elite treatments approachable, mental wellness might finally be getting the upgrade it deserves.
Click here to learn more about Exomind
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

Yahoo

timean hour ago

  • Yahoo

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs. Sign in to access your portfolio

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

Yahoo

timean hour ago

  • Yahoo

Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment

By Jacob Gronholt-Pedersen COPENHAGEN, DENMARK (Reuters) -Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks. Novo's shares rose as much as 5% at opening and were trading 3.5% higher by 0711 GMT. Three weeks ago, investors wiped $70 billion off its market value, after Novo - which became Europe's most valuable listed company following the launch of Wegovy in 2021 - issued a profit warning and named a company veteran as new CEO. On Friday, the U.S. Food and Drug Administration granted accelerated approval for Wegovy to treat metabolic dysfunction-associated steatohepatitis, or MASH, making it the first GLP-1 class therapy cleared for the progressive liver condition that affects around 5% of adults in the United States. Rival Eli Lilly has published encouraging MASH data in a mid-stage trial with tirzepatide - the active ingredient in its popular diabetes drug Mounjaro and weight-loss treatment Zepbound. "It is expected that this market exclusivity will only last for a transitional phase before Eli Lilly also launches a product on the market," said Nordnet analyst Per Hansen. Novo has also applied this year for approval in Europe and Japan. Its shares have lost more than two-thirds of their value since June last year, amid concerns that the Danish drugmaker is losing ground in the obesity drug race it started to rival Eli Lilly and "compounded" copycat drugs. Sign in to access your portfolio

FDA Warns of Future Action on Animal-Derived Thyroid Drugs
FDA Warns of Future Action on Animal-Derived Thyroid Drugs

Medscape

time2 hours ago

  • Medscape

FDA Warns of Future Action on Animal-Derived Thyroid Drugs

The top US regulator of medicines this week said he wants to officially approve an animal-derived thyroid drug, seemingly addressing concerns sparked by a press release from his own agency. On August 6, the FDA sent letters to manufacturers, importers, and distributors of animal-derived thyroid medications, stating that the agency 'intends to take action against marketed unapproved animal-derived thyroid (ADT) products (sometimes described as desiccated thyroid extract [DTE] products).' 'Due to their complex biological origin, these medications contain many compounds that are uncharacterized for safety and effectiveness,' the FDA said, noting that it could take as long as '12 months to safely transition patients to an FDA-approved thyroid hormone replacement product.' 'FDA is not taking immediate action against manufacturers who make unapproved animal-derived thyroid medication to give patients time to transition to an FDA-approved medication to treat their hypothyroidism,' the agency said. Following this announcement, in an August 13 post on his verified account on X, FDA Commissioner Marty Makary wrote that his agency 'is committed to pursuing the first-ever approval of desiccated thyroid extract, pending results of the ongoing clinical trials' and 'will in the meantime ensure access for all Americans,' without specifying what kind of thyroid medications would be available. The X post came after considerable social media backlash to the FDA's plans to shift patients toward synthetic thyroid medications and away from animal-derived versions. FDA-approved laboratory-made, or synthetic, thyroid medications currently dominate the US market. About 22 million people received prescriptions for levothyroxine through outpatient retail pharmacies in 2024 compared to an estimated 1.5 million patients who received prescriptions for animal-derived versions, the FDA said. Marketed under names such as Armour Thyroid, NP Thyroid, Nature-Thyroid, and Natural Thyroid, these medications are produced from dried, ground animal thyroid glands, usually those of pigs. Complex History The FDA has had a long and challenging history with regulating thyroid medicines. These drugs were first sold in the US well before federal laws gave the FDA the regulatory powers it now has, Antonio Bianco, MD, PhD, of the University of Texas Medical Branch, Galveston, Texas, and former president of the American Thyroid Association, told Medscape Medical News . 'Because they existed before the FDA, their regulatory pathway is really complicated,' Bianco said. In 1965, four of every five prescriptions for thyroid hormone were for natural thyroid preparations, as pharmacologic authorities confirmed that these were highly effective, well-absorbed, and produced clinically predictable outcomes, wrote Roselyn Cristelle Mateo-Collado, MD, of Rush University, Chicago, and James V. Hennessey, MD, of Harvard Medical School, Boston, in a 2019 review in Endocrine . But reports of patients not responding to desiccated thyroid triggered concerns about inconsistencies in the potency of these tablets, they added. Over time, a newer synthetic version, levothyroxine, became more widely used, even with concerns arising as well about inconsistent potency. Between 1987 and 1994, the FDA received 58 adverse experience reports associated with the potency of orally administered levothyroxine products. In 1997, the FDA mandated that any company wishing to market levothyroxine must first secure agency approval. In 2002, Abbott Laboratories received approval to keep selling its levothyroxine drug, Synthroid, which had been on the market for more than 40 years and was being taken by about 8 million people in the US, Abbott said at the time. In 2013, Abbott spun off its drug business as AbbVie. AbbVie now markets both Synthroid and Armour Thyroid, a desiccated thyroid drug. What's Next? In his X post, the FDA chief Makary did not mention any specific studies that he expects to lead to approval of a desiccated thyroid drug. AbbVie is sponsoring a phase 2/3 study examining the safety of its Armour Thyroid against the synthetic thyroid medicine, according to the website. AbbVie declined to comment on this story. Other companies also are working on research studies for their animal-derived thyroid drugs, so the FDA's August 7 announcement came as an unwelcome surprise for many people, Bianco said. Makary's X post this week likely was meant to respond to pushback from supporters of the animal-derived drugs, he added, noting that the commissioner's tone may signal that the agency is 'correcting course' and minimizing the impact of the agency's announcement. 'The manufacturers are working very hard' on large-scale trials, Bianco said. 'They require money and time to be done properly, and I think that's what the FDA should be stimulating.' Bianco reported being a consultant for AbbVie, Acella, Aligos, and Synthonics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store